Cytocom, Inc. a specialty biotech company, founded by patients, specializing in repurposing of drugs that deploys our patented therapies focused on the activation and rebalancing of the body’s immune system. Stimulating the body’s immune system remains one of the most promising approaches in the treatment of Cancers, HIV, Autoimmune Diseases, inflammatory conditions and other chronic infectious diseases.

We believe Cytocom has established a pipeline of novel drugs targeting chemokine and cytokines receptors in the pharmaceutical industry. Our compounds are designed to be highly potent, selective to minimize the risk of off-target effects and orally available for improved patient compliance.